Indication
Colitis
54 clinical trials
42 products
1 drug
Clinical trial
A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of Oral Ozanimod to Evaluate Efficacy and Long-term Safety in Japanese Subjects With Moderately to Severely Active Ulcerative ColitisStatus: Active (not recruiting), Estimated PCD: 2025-03-13
Product
OzanimodClinical trial
A Randomized, Double-Blind, Placebo-Controlled, Single, Repeat Dose Escalation and Indomethacin Challenge Study to Evaluate Safety, Tolerability and Pharmacokinetics of GSK4381406 in Healthy ParticipantsStatus: Withdrawn, Estimated PCD: 2024-12-05
Product
PlaceboProduct
IndomethacinProduct
GSK4381406Clinical trial
Effectiveness of Etrasimod on Disease Activity and Patient-reported Outcomes in Ulcerative Colitis - EFFECT-UCStatus: Not yet recruiting, Estimated PCD: 2027-04-01
Product
EtrasimodProduct
VE202Clinical trial
Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of VE202 in Patients With Mild-to-Moderate Ulcerative ColitisStatus: Recruiting, Estimated PCD: 2025-07-31
Clinical trial
A Phase 2a Randomized, Double-blind, Active-controlled, Parallel-group, Multicenter, Proof-of-concept Clinical Study to Evaluate the Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative ColitisStatus: Completed, Estimated PCD: 2020-12-01
Product
GuselkumabProduct
GolimumabProduct
VancomycinProduct
MesalazineClinical trial
A Randomised, Double-blind, Double-dummy, Multicentre, Phase III, Non Inferiority Trial of an Oral Mesalazine Formulation in Patients With Active Mild to Moderate Ulcerative Colitis for the Induction of Remission.Status: Not yet recruiting, Estimated PCD: 2025-08-01
Product
JNJ-77242113Clinical trial
A Phase 2b Multicenter, Randomized, Placebo- Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative ColitisStatus: Recruiting, Estimated PCD: 2025-05-27
Clinical trial
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects With Moderate to Severe Crohn's DiseaseStatus: Terminated, Estimated PCD: 2022-12-12
Product
BMS-986165Clinical trial
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Subjects With Moderate to Severe Ulcerative ColitisStatus: Terminated, Estimated PCD: 2023-05-31
Product
KHK4083Clinical trial
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Multiple Ascending Dose Study (Induction Therapy) & Long-term Extension Therapy of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderately Active UCStatus: Completed, Estimated PCD: 2018-09-01
Product
TEV-48574Clinical trial
A 14 Week Phase 2b, Randomized, Double-Blind, Dose-Ranging Study to Determine the Pharmacokinetics, Efficacy, Safety and Tolerability of TEV-48574 in Adult Patients With Ulcerative Colitis or Crohn's Disease (RELIEVE UCCD)Status: Recruiting, Estimated PCD: 2024-12-16
Product
VedolizumabClinical trial
A Randomized, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of Vedolizumab Intravenous as Maintenance Therapy in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous TherapyStatus: Recruiting, Estimated PCD: 2025-08-30
Clinical trial
A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of 3 Active Dose Regimens of MORF-057 in Adults With Moderately to Severely Active Ulcerative Colitis (EMERALD-2)Status: Recruiting, Estimated PCD: 2025-05-01
Product
MORF-057Clinical trial
Phase III Study of AJM300 in Patients With Active Ulcerative ColitisStatus: Completed, Estimated PCD: 2020-11-09
Product
KSP-0243Clinical trial
An Early Phase 2 Clinical Study of KSP-0243 in Patients With Mild to Moderate Active Ulcerative ColitisStatus: Recruiting, Estimated PCD: 2025-03-01
Product
LMT503Clinical trial
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose, Multiple Ascending Dose and Food Effect Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LMT503 in Healthy SubjectsStatus: Not yet recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Phase 3b Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab Subcutaneous in Subjects With Ulcerative Colitis and Crohn's DiseaseStatus: Active (not recruiting), Estimated PCD: 2024-04-23
Clinical trial
A Phase 4, Prospective, Open-label Study of Ozanimod to Explore the Safety, Efficacy, Quality of Life, and Biomarker Response in Participants With Moderate to Severe Ulcerative Colitis in Clinical PracticeStatus: Recruiting, Estimated PCD: 2024-11-29
Product
AJM300Clinical trial
A Placebo-controlled, Double-blind, Randomised Study to Assess the Efficacy and Safety of Cobitolimod as an add-on to Current Practice in Chronic Active Treatment Refractory Ulcerative Colitis PatientsStatus: Completed, Estimated PCD: 2013-06-01
Product
CobitolimodClinical trial
Organization of Teratology Information Specialists (OTIS) Vedolizumab Pregnancy Exposure RegistryStatus: Completed, Estimated PCD: 2022-07-15
Product
Other Biological AgentProduct
VTX002Clinical trial
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Clinical Efficacy and Safety of VTX002 in Subjects With Moderately to Severely Active Ulcerative ColitisStatus: Active (not recruiting), Estimated PCD: 2023-08-30
Clinical trial
PERFUSE - One-year Persistence to Treatment of Patients Receiving Flixabi or Imraldi: a French Cohort StudyStatus: Completed, Estimated PCD: 2022-06-30
Clinical trial
A Phase 4 Open-Label Study to Evaluate Vedolizumab IV Dose Optimization on Treatment Outcomes In Nonresponders With Moderately to Severely Active Ulcerative Colitis (ENTERPRET)Status: Completed, Estimated PCD: 2020-10-16
Product
InfliximabProduct
AdalimumabClinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative ColitisStatus: Completed, Estimated PCD: 2018-08-10
Product
UstekinumabClinical trial
An Adaptive Phase 2, Randomized, Double Blind, Placebo Controlled Study of LY3471851 (NKTR 358) in Patients With Moderately to Severely Active Ulcerative ColitisStatus: Terminated, Estimated PCD: 2022-08-09
Clinical trial
An Open Label, Long Term Safety Trial of BI 655130 (SPESOLIMAB) Treatment in Patients With Moderate to Severely Active Ulcerative Colitis Who Have Completed Previous BI 655130 TrialsStatus: Completed, Estimated PCD: 2023-05-03
Product
SpesolimabClinical trial
A Randomized, Multi-center, Subject and Investigator-blinded, Placebo-controlled, Parallel-group Study to Assess the Efficacy Safety and Tolerability of LYS006 in Patients With Mild to Moderate Ulcerative ColitisStatus: Terminated, Estimated PCD: 2022-11-07
Product
LY3471851Product
LYS006Clinical trial
Pan-EU Real-World Experience With Imraldi®Status: Completed, Estimated PCD: 2021-11-30
Clinical trial
A Phase 2a, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, and Tolerability of MORF-057 in Adults With Moderately to Severely Active Ulcerative Colitis (EMERALD-1)Status: Active (not recruiting), Estimated PCD: 2023-10-18
Product
PF-06480605Clinical trial
A PHASE 2A, MULTICENTER, SINGLE ARM, OPEN- LABEL, TWO-STAGE, STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06480605 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITISStatus: Completed, Estimated PCD: 2018-05-31
Clinical trial
Effectiveness of Ustekinumab in Patients Suffering From Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) With Extra-intestinal Manifestations or Immune-mediated Inflammatory Diseases in a Real-world SettingStatus: Completed, Estimated PCD: 2023-03-17
Clinical trial
Entyvio (Vedolizumab IV) Extended Access Program in Ulcerative Colitis and Crohn's DiseaseStatus: Terminated, Estimated PCD: 2023-01-03
Clinical trial
A Pilot Study Testing the Safety and Feasibility of Restorative Microbiota Therapy (RMT) in Patients With Refractory Immune-checkpoint Inhibitor-related ColitisStatus: Not yet recruiting, Estimated PCD: 2024-12-01
Product
RMTClinical trial
Using Fluorescently Labeled Vedolizumab to Visualize Local Drug Distribution During Colonoscopy and Identify Mucosal Target Cells in Patients With Inflammatory Bowel DiseaseStatus: Completed, Estimated PCD: 2022-10-01
Clinical trial
De-escalation of Anti-TNF Therapy in Adolescents and Young Adults With IBD With Tight Faecal Calprotectin and Trough Level MonitoringStatus: , Estimated PCD: 2025-03-01
Clinical trial
VERDICT: In actiVE Ulcerative Colitis, a RanDomIzed Controlled Trial for Determination of the Optimal Treatment TargetStatus: Recruiting, Estimated PCD: 2025-03-31
Product
Treatment Algorithm AProduct
Treatment Algorithm BProduct
Treatment Algorithm CClinical trial
A Multi-Center, Prospective, Non-Interventional Study of Real-World Effectiveness of Etrasimod in Patients With Ulcerative Colitis (ENDEAVOUR-UC)Status: Not yet recruiting, Estimated PCD: 2027-05-04
Clinical trial
An Open-label Study of Tofacitinib for the Treatment of Refractory Immune-related Colitis From checKpoint Inhibitor Therapy (TRICK)Status: Recruiting, Estimated PCD: 2025-05-30
Product
TofacitinibClinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants With Moderately to Severely Active Ulcerative ColitisStatus: Active (not recruiting), Estimated PCD: 2024-04-02
Clinical trial
Oral 5-aminosalicylic Acid Withdrawal in Long Standing Inactive Ulcerative Colitis: A Double-blind, Randomized, Placebo-controlled TrialStatus: Completed, Estimated PCD: 2021-09-10
Clinical trial
Pharmacologic Weight Loss as Adjunct Therapy for Ulcerative Colitis in Obese Patients: A Phase 2A, Randomized, Placebo-Controlled TrialStatus: Recruiting, Estimated PCD: 2024-06-30
Product
Phentermine-TopiramateDrug
VarlilumabClinical trial
Fecal Microbiota Transplantation (FMT) for Immune-Checkpoint Inhibitor Induced-Diarrhea/Colitis in Genitourinary Cancer PatientsStatus: Recruiting, Estimated PCD: 2025-12-31
Product
LoperamideClinical trial
Detection of Herpesvirus DNA (CMV, EBV, HHV-6 and HSV) in Colonic Tissue: Impact on Ulcerative Colitis Flare-upStatus: Active (not recruiting), Estimated PCD: 2024-03-13
Product
biopsiesProduct
Blood SampleClinical trial
Therapeutic Modulation of the Intestinal Creatine Kinase System in Inflammatory Bowel Disease (IBD)Status: Withdrawn, Estimated PCD: 2023-03-01
Product
Creatine monohydrateClinical trial
Multicenter Retrospective Cohort Study on Patients Receiving Extracorporeal Photopheresis for Immune-related Adverse Events After Checkpoint Inhibitor TreatmentStatus: Completed, Estimated PCD: 2022-12-30
Product
ECPClinical trial
A Phase 2/3, Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Oral Ozanimod (RPC1063) in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis With an Inadequate Response to Conventional TherapyStatus: Recruiting, Estimated PCD: 2026-05-22
Clinical trial
A Phase 2b Randomized, Double-blind, Active-and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative ColitisStatus: Recruiting, Estimated PCD: 2025-05-27
Product
JNJ-78934804Clinical trial
A Phase 3, Multicenter, Open-label, Basket, Long-term Extension Study of Ustekinumab in Pediatric Clinical Study Participants (2 to <18 Years of Age)Status: Recruiting, Estimated PCD: 2027-09-29
Clinical trial
An Observational Study to Assess the Long-term Safety of Ustekinumab Versus Other Biologic Therapies Among Patients With Crohn's Disease and Ulcerative Colitis: A New-User Cohort Study Using the Department of Defense Electronic Health Records DatabaseStatus: Recruiting, Estimated PCD: 2029-08-31
Product
Other Biologic TherapiesClinical trial
A Phase 3 Randomized, Open-label Induction, Double-blind Maintenance, Parallel-group, Multicenter Protocol to Evaluate the Efficacy, Safety, and Pharmacokinetics of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative ColitisStatus: Recruiting, Estimated PCD: 2028-05-22
Clinical trial
A Phase 3 Randomized, Open-Label Study to Assess the Efficacy, Safety, and Pharmacokinetics of Golimumab Treatment, a Human Anti-TNFα Monoclonal Antibody, Administered Subcutaneously in Pediatric Participants With Moderately to Severely Active Ulcerative ColitisStatus: Active (not recruiting), Estimated PCD: 2024-06-20
Clinical trial
A Phase 3 Study of the Efficacy, Safety and Pharmacokinetics of Ustekinumab as Open-label Intravenous Induction Treatment Followed by Randomized Double-blind Subcutaneous Ustekinumab Maintenance in Pediatric Participants With Moderately to Severely Active Ulcerative ColitisStatus: Active (not recruiting), Estimated PCD: 2025-07-24
Clinical trial
Randomized, Multicenter Study to Investigate the Efficacy of Dashboard Driven Individualized Dosing of Infliximab Compared To Standard Dosing During the Induction in Patients With Acute Severe Ulcerative ColitisStatus: Recruiting, Estimated PCD: 2024-12-31